Alza finds more it likes at Alkermes
The deal is the second this year between the two companies, and could bring AZA's total investment in its ALKS partnership to $110 million. In February, AZA gained a 9.7 percent interest in ALKS through the purchase of $50 million newly issued, unregistered shares of ALKS. Simultaneously, the companies agreed to develop and commercialize an undisclosed product using one of two of ALKS' drug delivery technologies, ProLease or Medisorb.
Under the new agreement, AZA (Palo Alto,